ARS Pharmaceuticals Inc - Rentabilitas operasi SPRY

SPRY (ARS Corp) - tandha merek perusahaan

The emergency allergy relief market is expanding as patients shift toward needle-free sprays, where ARS Pharmaceuticals (SPRY) is setting the trend for convenience. The operating margin timeline demonstrates business efficiency, with the value of -161.50 serving as the current metric. The company's success is based on scaling Neffy sales, expanding insurance coverage, and increasing market share by displacing injectors.

SPRY: Tingkat bathi operasi ars-pharma.com 28.04.2023 - 19.11.2026

ars-pharma.com - rincian analitis lan metrik utama (SPRY)

Analisis komprehensif perusahaan:ARS Pharmaceuticals Inc, SPRY
Barang utama ARS Pharmaceuticals

When assessing the asset quality of ARS Pharmaceuticals (SPRY), I focus on the efficiency of cost management. By analyzing the operating profit margin, an investor can see the portion of revenue remaining after paying operating expenses, before taxes and interest. This metric measures the intrinsic profitability of the business model. For ARS Pharmaceuticals, this indicator reflects the commercial potential of introducing the innovative Neffy spray into emergency medicine. Margin growth confirms the high capitalization of the company's intellectual property.

Pesaing utama

Rentabilitas operasi haleon.com|Rentabilitas operasi KVUE|Rentabilitas operasi Verona Pharma (VRNA)|Jyong Biotech (MENS) - Tingkat bathi adhedhasar bathi operasi|Margin operasi LGND (Ligand Pharma)|Amneal Pharmaceuticals Inc - Rentabilitas operasi|PRGO - Rentabilitas operasi|Alvotech Corp (ALVO) - Margin dodolan operasi|LQDA: Margin operasi|Rentabilitas dodolan operasi glpg.com (GLPG)|Rentabilitas operasi ANI Pharmaceuticals Inc|MNKD: Tingkat bathi operasi|Margin dodolan operasi AMPH (Amphastar)|PCRX - Rentabilitas dodolan operasi|Theravance Biopharma - Margin dodolan operasi|Rasio bathi operasi AQST (Aquestive Therapeutics)|SCPH: Margin dodolan operasi|Rentabilitas dodolan operasi Tectonic Therapeutic|TNXP: Margin operasi|SXT China (SXTC) - Margin operasi|Rentabilitas operasi eupraxiapharma.com|BioHarvest Sciences (BHST) - Rentabilitas kegiatan operasi|Rentabilitas operasi Invizyne (EXOZ)|ORMP - Rentabilitas dodolan operasi|Margin operasi ENTX (Entera Bio)|Tingkat bathi adhedhasar bathi operasi MindWalk Therapeutics|ABVC: Margin dodolan operasi|CPIX - Margin operasi|QNTM (Quantum BioPharma) - Margin dodolan operasi|Margin bathi operasi FGEN (FibroGen)|TELO (Telomir Pharmaceuticals Corp) - Margin operasi|Margin operasi ranitherapeutics.com|Rentabilitas operasi Synergy CHC Corp. (SNYR)|Rallybio Corp - Rentabilitas dodolan miturut bathi operasi|lexariabioscience.com - Margin dodolan operasi|Margin operasi Pulmatrix Inc PULM|Pheton Holdings - Margin operasi|Margin bathi operasi APM|Lyra Therapeutics, Inc. (LYRA) - Rentabilitas operasi|Rentabilitas dodolan operasi Impact BioMedical, Inc. (IBO)|Rentabilitas operasi TNF Pharma|YCBD: Tingkat bathi operasi|Margin operasi PRFX|CYTO - Rentabilitas dodolan operasi|Rentabilitas operasi Lipella LIPO|Rasio bathi operasi OPTN (OptiNose, Inc.)|PIRS - Rentabilitas operasi|Procaps (PROC) - Margin dodolan operasi|PTPI: Margin operasi|Qilian International (QLI) - Margin operasi|Rentabilitas operasi Acelyrin, Inc.|Margin operasi TFF Pharmaceuticals, Inc.